Pfizer licenses discontinued ADC to Medicus as Revolution Medicines updates lung-cancer data

Pfizer licensed worldwide rights to its discontinued PF-08046031 (CD228V), an early-stage antibody-drug conjugate originally developed by Seagen, to Medicus Pharma.

The agreement includes $12 million upfront, another $15 million due in September 2027, and more than $1 billion in potential development, regulatory, and sales milestones. Pfizer also provided $2 million in development funding and will receive tiered low-double-digit royalties on net sales.

Medicus will assume responsibility and costs for developing, manufacturing, securing approval for, and commercializing the ADC. PF-08046031 targets melanotransferrin/CD228, which is highly expressed in melanoma and several solid tumors; there are currently no approved CD228-targeted drugs.

Separately, Revolution Medicines reported updated lung-cancer data for its RAS(ON) inhibitor portfolio. In previously treated NSCLC, zoldonrasib showed a preliminary 61% objective response rate and 89% disease-control rate in a small efficacy-evaluable KRAS G12D group.

For previously treated KRAS G12C-mutant NSCLC, elironrasib monotherapy produced a 56% objective response rate, 94% disease-control rate, and estimated median progression-free survival of 9.9 months at the reported dose.

Revolution also highlighted combination programs involving daraxonrasib and elironrasib, including combinations with pembrolizumab and an investigational RAS(ON) doublet. The results are early clinical data and require confirmation in larger studies.